Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Satyajit Kosuri, MD, Sang Mee Lee, PhD, Hongtao Liu, MD PhD, Mylove Mortel, MS, RN, Lucy A Godley, MD PhD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Wendy Stock, MD, Justin Kline, MD, Peter A. Riedell, MD, Koen Van Besien, MD PhD, Michael R. Bishop, MD, Andrew S. Artz, MD

Blood (2019) 134 (Supplement_1): 3324.

https://doi.org/10.1182/blood-2019-126211

Published: 2019

Journal Articles

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Amy Wang, MD MPH, Howard Weiner, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew S Artz, MD, Michael R. Bishop, MD, Lucy Godley, MD PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Jane Churpek, MD, Emily K Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MD PhD

Blood (2018) 132 (Supplement 1): 4073.

https://doi.org/10.1182/blood-2018-99-120244

Published: 2018

Journal Articles

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Hongtao Liu, MD PhD, Andrew Artz, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, Wendy Stock, MD, Michael R. Bishop, MD

Blood (2017) 130 (Supplement 1): 3312.

https://doi.org/10.1182/blood.V130.Suppl_1.3312.3312

Published: 2017

Journal Articles

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Kothari Shawn, MD, Andrew Artz, MD, Sang Mee Lee, PhD, Noreen Fulton, BS, Jae-Hyun Park, Wendy Stock, MD, Richard A. Larson, MD, Olatoyosi Odenike, MD, Justin Kline, MD, Lucy Godley, MD PhD, James LaBelle, MD PhD, Satyajit Kosuri, MD, Peter A Riedell, MD, Yusuke Nakamura, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2017) 130 (Supplement 1): 4572.

https://doi.org/10.1182/blood.V130.Suppl_1.4572.4572

Published: 2017

Journal Articles

Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Gunjan L. Shah, MDMS, Michael Scordo, MD, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Molly A. Maloy, MS, Jimmy Nieves, RN, Sean Devlin, PhD, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Miguel-Angel Perales, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Sergio A. Giralt, MD, Roni Tamari, MD

Blood (2016) 128 (22): 1236.

https://doi.org/10.1182/blood.V128.22.1236.1236

Published: 2016

Journal Articles

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Michael Scordo, MD, Gunjan Shah, MD M.S., Molly A. Maloy, MS, Sean Devlin, PhD, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Brian C. Shaffer, MD, Boglarka Gyurkocza, MD, Hugo R. Castro-Malaspina, MD, Roni Tamari, MD, Sergio A. Giralt, MD, Miguel Perales, MD

Blood (2016) 128 (22): 2194.

https://doi.org/10.1182/blood.V128.22.2194.2194

Published: 2016

Journal Articles

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Michael Scordo, MD, Gunjan L. Shah, MDMS, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Sean Devlin, PhD, Molly A. Maloy, MS, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Boglarka Gyurkocza, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD, Miguel Perales, MD, Sergio A. Giralt, MD, Brian C. Shaffer, MD

Blood (2016) 128 (22): 4621.

https://doi.org/10.1182/blood.V128.22.4621.4621

Published: 2016

Journal Articles

Prospective Evaluation of Cord Blood (CB) & Haplo-Identical Donor Availability Reveals Compromised Donor Access for Both Graft Types in Minorities and High Rates of Failure to Clear Haplo Donors in Adult Patients

Satyajit Kosuri, MD, Tara F. Wolff, MS, NP-BC, Courtney Byam, BS, CHTC, Emily Lauer, BS, BA, Yeon Yoo, BS, Miguel-Angel Perales, MD, Sergio A. Giralt, MD, Andromachi Scaradavou, MD, Doris M Ponce, MD, Juliet N. Barker, MBBS (Hons)

Blood (2015) 126 (23): 2027.

https://doi.org/10.1182/blood.V126.23.2027.2027

Published: 2015

Journal Articles

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Guenther Koehne, MDPhD, Satyajit Kosuri, MD, Ekaterina Doubrovina, MD PhD, Tao Dao, PhD, Andrew Scott, Achim A Jungbluth, MD, Richard J O'Reilly, MD

Blood (2015) 126 (23): 98.

https://doi.org/10.1182/blood.V126.23.98.98

Published: 2015

Journal Articles

Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies

Blood (2015) 126 (23): 3231.

https://doi.org/10.1182/blood.V126.23.3231.3231

Published: 2015

Journal Articles

Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Satyajit Kosuri, MD, Boglarka Gyurkocza, MD, Sean Devlin, PhD, Molly Maloy, MS, Cristi Ciolino, MPH CCRP, Taylor Borrill, BA, Ann A. Jakubowski, MD PhD, Esperanza B Papadopoulos, MD, H.R. Castro-Malaspina, MD, Guenther Koehne, MD PhD, Miguel-Angel Perales, MD, Sergio Giralt, MD

Blood (2015) 126 (23): 3095.

https://doi.org/10.1182/blood.V126.23.3095.3095

Published: 2015

Journal Articles

The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Jonathan Peled, MD PhD, Eric R. Littman, Lilan Ling, Satyajit Kosuri, MD, Molly Maloy, MS, Sergio A. Giralt, MD, Juliet N. Barker, MBBS (Hons), Miguel-Angel Perales, MD, Ying Taur, MD, Eric Pamer, Marcel van den Brink, MD PhD, Robert R. Jenq, MD

Blood (2015) 126 (23): 744.

https://doi.org/10.1182/blood.V126.23.744.744

Published: 2015

Journal Articles

Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant

Satyajit Kosuri, MD, Katherine M Smith, BA, Deborah Kuk, MS, Sean M. Devlin, PhD, Peter G. Maslak, M.D., Sergio Giralt, MD, Guenther Koehne, MD, PhD

Blood (2013) 122 (21): 4647.

https://doi.org/10.1182/blood.V122.21.4647.4647

Published: 2013

NARROW

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS

Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

Selinexor Maintenance Is Feasible and Tolerable after Allogeneic Stem Cell Transplant (allo-SCT) for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Dose Escalation Prophylactic Donor Lymphocyte Infusion (pDLI) after T-Cell Depleted (TCD) Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Is Feasible and Results in Higher Donor Chimerism, Faster Immune Re-Constitution and Prolonged PFS

Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Prospective Evaluation of Cord Blood (CB) & Haplo-Identical Donor Availability Reveals Compromised Donor Access for Both Graft Types in Minorities and High Rates of Failure to Clear Haplo Donors in Adult Patients

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies

Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only